Advertisement
Advertisement
U.S. markets open in 5 hours 20 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.6700-0.0400 (-1.48%)
At close: 4:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.7100
Open2.7200
Bid0.0000 x 2900
Ask0.0000 x 3100
Day's Range2.6600 - 2.7000
52 Week Range2.1500 - 4.1300
Volume545,351
Avg. Volume787,035
Market Cap249.137M
Beta (5Y Monthly)0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.7970
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.28
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTIC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CTI BioPharma Corp.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
  • PR Newswire

    CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on October 14, 2021, in accordance

  • Insider Monkey

    10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital

    In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

  • Zacks

    CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

    CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

Advertisement
Advertisement